Copland Road Capital Corporation focuses on investments in the cannabis sector, primarily in the U.S. While it boasts a strong liquidity position with a current ratio of 18.47 and zero debt, its negative return on equity (ROE) and return on assets (ROA) indicate operational inefficiencies. The market cap of $1.44M and stagnant price suggest limited investor confidence. Overall, the company has solid financial health metrics, but the negative profitability raises concerns about its long-term viability in a competitive industry.
Loading financial metrics...
Company posted a loss of $-390K over the last year, representing Infinity% of revenue.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 18.5x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q2 (June 30, 2025)